The kinetics of germ-cell development were examined in random-bred adult Swiss mice by means of tritium autoradiography. Comparisons were made between males with normal (+/+) and abnormal karyotypes: Rb(l 1.13)4Bnr/+ and T(1;13)70H/+ heterozygotes, T70H tertiary trisomies, andT70H translocation trisomies. The time taken for the first wave of labelled cells to progress from premeiotic S-phase to diplotene and then on to the second meiotic metaphase was estimated in each stock, and rates of increase of labelled meiotic figures were measured. The S-phase to diplotene interval did not differ significantly among the different genotypes, taking from 10 days, 16 h to 10 days, 19 h. In Rb4Bnr/+, T70H translocation trisomic, and T70H tertiary trisomic males, however, labelled meiotic figures accumulated at a lower rate, particularly in the tertiary trisomies. A cell delay for some meiocytes was thus indicated during meiotic prophase. A correlation was seen between the degree of meiotic delay and severity of reduction in sperm count. The period from late diplotene to metaphase II was also found to be longer in T70H tertiary trisomies than in controls (+/+) or other chromosomally abnormal males.

This content is only available via PDF.
© 1983 S. Karger AG, Basel
1983
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.